| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C50H99NO7 |
| Purity | |
| SMILES | |
| Form | Viscous Liquid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Ionizable lipid-2 is a cationic lipid for nucleic acid delivery, capable of forming lipid nanoparticle mRNA vaccines that exhibit in vitro stability and immunostimulatory activity. It can be used in studies related to herpes zoster, mRNA vaccines and nucleic acid delivery[1]. It is supplied as a colorless to light yellow viscous liquid (C50H99NO7, MW 826.32) at 99.64% purity.
Physical & Chemical Properties
| CAS Number | 2763904-72-7 |
|---|---|
| Molecular Formula | C50H99NO7 |
| Molecular Weight | 826.32 g/mol |
| Purity | 99.64% |
| Appearance | Viscous Liquid |
| Color | Colorless to light yellow |
| SMILES | O=C(OCC(CCCCCCCC)CCCCCC)OCCCCCCN(CCCCCCOC(OCC(CCCCCCCC)CCCCCC)=O)CCCCO |
| Signaling Pathway | Metabolic Enzyme/Protease |
| Solubility | In Vitro: DMSO: ≥ 100 mg/mL (121.02 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) * "≥" means soluble, but saturation unknown. |
| Storage | Pure form: -20°C, 3 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
[1]. Haomeng Wang, et al. Preparation of ionizable lipid compound for nucleic acid delivery and its LNP composition and vaccine. CN116514672A. 2023-08-01.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | ≥ 100 mg/mL (121.02 mM) | use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
Data provided by the manufacturer.
In Vitro
Microfluidic mixing encapsulates VZV gE mRNA in a lipid mixture solution that combines Ionizable lipid-2, DSPC, cholesterol, and other components. Compared with cationic lipids III, IV, and V, the resulting LNP-mRNA vaccine achieves greater encapsulation efficiency, together with suitable average particle size, PDI, and Zeta potential[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
